Business Wire

First Photorealistic AI Avatar for People Living with Alzheimer’s and Dementia Launched by Lenovo and Innovations in Dementia

Share

Today at Lenovo Tech World, Lenovo™ in collaboration with Innovations in Dementia, launched Alzheimer’s Intelligence, a photorealistic 3D avatar with custom AI based on the lived experiences of people with dementia and Alzheimer’s. This proof-of-concept project gives people and families navigating a diagnosis of dementia 24-hour access to a conversational avatar that offers curated advice that prioritizes accuracy, privacy, and compassion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241015879964/en/

'Liv' the Alzheimer's intelligence avatar being used by Ahmad Krayem, one of the focus group participants involved in the Lenovo project. (Photo: Business Wire)

“Globally there are around 55 million people living with dementia, and that number is expected to reach 139 million by 2050,” said Dr. David Llewellyn, Professor of Clinical Epidemiology and Digital Health. "The AI advancements in Lenovo's 'Alzheimer’s Intelligence' initiative demonstrate how technology has the potential to enhance human interaction, offering a valuable tool to support individuals living with dementia, both in the present and future."

In this first-of-its-kind application, Lenovo pioneered the use of AI made possible by its comprehensive portfolio of technology solutions, from individual to enterprise. The combined technology aggregates firsthand experience and advice from hundreds of real people living with dementia and Alzheimer’s into a responsive, photoreal 3D avatar capable of having an unscripted, natural conversation. With this proof of concept, a person diagnosed with dementia is just a click away from a real-time conversational resource and aid.

“With recent and ever-growing advancements in AI, we must harness this technology purposefully and responsibly for communities that may be overlooked by innovative technology,” said Doug Fisher, Chief Security and AI Officer at Lenovo. “This is part of our commitment to delivering Smarter AI for All—developing and deploying technology that can empower everyone at every scale.”

The avatar was created from a composite of images of 10 people living with dementia and Alzheimer’s. From the initial pose of each image, generative AI extrapolated faces for several thousand other expressions and angles inspired by the subject. These were then aggregated into one dataset, which blends with the face of a filmed performer to create the image of "Liv," the AI avatar.

A large language model (LLM) dataset of the advice Liv can impart was created using data that came directly from experiences of people living with dementia, including entries from Innovations in Dementia’s Dementia Diaries project and in-depth panel interviews. Each time a user asks a question (via Speech-to-text), the LLM queries the dataset to provide text-based answers to the user's question, expressed using the language of the "persona" created for Liv, and based on the knowledge base built for Liv. The replies are then voiced using a vocal synth created for the project. "Sentiment analysis" is used to analyse the underlying feeling of the reply, which is reflected in the facial expression of the AI when it speaks. Finally, real time 4k visual AI is used to allow the speech generated by the vocal synth to appear to be spoken in real time.

Alzheimer’s Intelligence will allow people who have recently been diagnosed with dementia to ask the questions that only someone who has lived with the disease can answer, including understanding day-to-day challenges, discussing the disease with family, and exploring new hobbies. Crucially, the entire experience was designed to be accessible, requiring minimal tech expertise and prioritizing natural, familiar interaction.

The avatar is currently being trialled by people with dementia in a controlled environment with the goal of making it more publicly available in the future. The making of the project and initial interactions have been captured in the films linked below.

The Alzheimer’s Intelligence project offers a new way to easily access valuable insight sourced from data based on real people living with dementia and Alzheimer’s. While the information is wide-ranging, the development team took great care to apply clear guardrails to the AI and ensure no medical advice is offered by the avatar. This included working closely with Dr. Llewellyn and Innovations in Dementia, who both advised and consulted on the avatar build and testing.

The AI was trained and tested for this specific use case, and the project was designed and brought to life with Lenovo devices, services, software, servers, and cloud solutions. This is the first time ever that Lenovo AI-ready solutions have come together to develop an avatar of this kind. Devices and solutions include:

  • Lenovo’s tech partner Kaleida, who led the development of the avatar and underlying AI, leveraged Lenovo’s AI professional services to support the processes and security
  • ThinkStation P7server, ThinkPad T14s Gen 6, and ThinkPad X1 Carbon Gen 12 AIPC laptops, as well as Lenovo Legion and ThinkVision monitors and accessories.

“When people are first diagnosed with dementia, they can feel lost, with so many questions about what is happening. This AI doesn’t replace human contact but what it does do is offer a knowledgeable and compassionate source of assurance and advice based directly on the experiences and wisdom of other people with dementia.” said Steve Milton, Director, Innovations in Dementia. “It’s great to see tech leaders like Lenovo prioritising such an innovative use of AI in a way that not only recognises and the expertise of people with dementia but harnesses it in such a unique way to support others when they need it most.”

Innovations in Dementia state that around 20% of people who come to them are under 65 and may live for many years with the condition. The NGO promotes a positive but realistic view of dementia: although it is life changing, it does not have to be life ending.

“We recognize the importance of giving everyone a voice in innovation,” commented Doug Fisher at Lenovo. “With huge advancements in AI and smarter technologies, now is the time to explore and pilot creative new ways to use technology like AI thoughtfully and responsibly, for the greater good. Ultimately, it’s about re-imagining a future where technology is for—and from—all, giving everyone a voice in what they want from the most transformative technology of our generation.”

Gail Gregory and Ahmad Krayem, focus group participants comment…

  • “It’s so important to have real people involved in the creation of the avatar. Because the people with dementia are the experts. We’re the ones living with it. You can’t just grab things from a textbook because it’s not real. It must be real. And the more realistic it is the more relatable it is. I think it is going to be a very useful tool, especially for people living on their own because they’ve got nobody to ask,” Gail Gregory.
  • “I want to help other people who have been recently diagnosed with dementia and reassure them that it is not something to be afraid of. A doctor can tell you what medication to take. But only people living with dementia, can tell you what they are exactly going through,” Ahmad Krayem.

Watch the Alzheimer’s Intelligence video here

The participants in this film include:

Gail Gregory: Diagnosed with Alzheimer’s at age 55, Gail also subverts the commonly-held stereotypes of a person living with dementia. She can broach serious topics with humour, and is candid in her opinions and struggles.

Ahmad Krayem: Ahmad was only diagnosed with early onset in his early 60s after insistence from his wife, who was a pharmacist, that he should go for a check-up. Ahmad found stopping work a big challenge and has been through a journey of denial and acceptance. He talks passionately about helping others who’ve gone through this.

Alzheimer’s Intelligence is a proof-of-concept tool and is not publicly available, but for anyone looking to hear from people living with Alzheimer’s or dementia diagnosis, can contact Innovations in Dementia (UK) or Alzheimer’s Association (US).

Examples of interactions with the avatar:

Q: I keep forgetting to take my pills. How can I remember?

A: It's quite common to forget things like taking medication. Perhaps setting a routine could help, like taking your pills with a meal or at the same time each day. You could also try setting an alarm or reminder on your phone. There are pill organisers, too, which can be useful. Would one of those options suit you, do you think?

Q: How do I talk about my diagnosis with friends and family?

A: Talking about your diagnosis with friends and family can be a daunting task, but it can also help to bring support and understanding. Start by sharing how you feel today and maybe a bit about what you've learned about your condition. Encourage them to ask any questions, as this can help them understand what you're going through. It’s okay to be honest about any fears or concerns you have, as well. Do you think that might be helpful?

About Lenovo

Lenovo is a US$57 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.

LENOVO, THINKSTATION, THINKPAD, and THINKVISION are trademarks of Lenovo. All other trademarks are the property of their respective owners. ©2024, Lenovo Group Limited. ©2024 Motorola Mobility LLC. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241015879964/en/

Contacts

Stuart Gill, sgill@lenovo.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai

HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release

Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa

SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release

On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e

Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release

TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye